ArticleFrontiers in oncology2024
Primary pulmonary hyalinizing clear cell carcinoma with
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Primary pulmonary hyalinizing clear cell carcinoma harboring EWSR1::ATF1 fusion: a case report.General thoracic and cardiovascular surgery cases · 2026Article
- A mediastinal eosinophilic adenoma misdiagnosed as an esophageal stromal tumor: A case report.Journal of cardiothoracic surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary pulmonary hyalinizing clear cell carcinoma (HCCC) is a rare type of primary salivary gland-type tumor of the lung. HCCC is characterized by unique pathological features, including nests, cords, or trabeculae of clear or eosinophilic tumor cells infiltrating a mucinous or hyalinized stroma. Additional analyses of this carcinoma have revealed positive epithelial markers via immunophenotyping and Case presentation: A 47-year-old female patient presented with a 2-month history of cough, sputum production, and dyspnea. A chest CT scan found a nodular soft tissue density shadow in the lower segment of the trachea. Subsequently, the patient underwent tumor resection via combined flexible and rigid bronchoscopy. Postoperative pathological examination, including immunohistochemistry and molecular testing, confirmed an Conclusions: Primary pulmonary HCCC is an extremely rare, low-grade malignant epithelial tumor of the lung, which has a notably difficult clinical diagnosis and treatment due to the absence of a standard treatment protocol. This case report presents a patient with primary pulmonary HCCC confirmed by molecular testing, aiming to raise awareness about this tumor among physicians and provide valuable clinical references.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.